| Drug Name: | Lansoprazole (103577-45-3) |
|---|---|
| PubChem ID: | 3883 |
| SMILES: | CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F |
| InchiKey: | MJIHNNLFOKEZEW-UHFFFAOYSA-N |
| Therapeutic Category: | Anti-Infective Agents, Anti-Ulcer Agents, Enzyme Inhibitors, Gastrointestinal Agents, Proton Pump Inhibitors |
| Molecular Weight (dalton) | : | 369.368 |
| LogP | : | 3.51522 |
| Ring Count | : | 3 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 67.87 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Imatinib (152459-95-5) | Oedema Labial Genital | Synergistic | lansoprazole is a weak inhibitor of CYP3A4, thus levels of imatinib were increased | Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category